Completed
PHASE4
INTERVENTIONAL
NCT01308619
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.
Interventions
Name:
Doxycycline
Type:
DRUG
Description:
doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
Name:
Placebo
Type:
OTHER
Description:
Placebo, oral, one capsule daily in the morning
Primary Outcomes
Measure:
Change From Baseline in Inflammatory Lesion Counts
TimeFrame:
baseline to week 12
Description:
Mean change in inflammatory lesion counts from baseline to week 12
Trial Information
NCT ID
NCT01308619
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Galderma R&D
Last Updated
December 15, 2025